The Quest Trial, a paradigm of HIV collaborative research

Nature Medicine

Volumn 6, Issue 11, 2000, Pages 1194-

  Goh, Li Ean ^a   McDade, Hugh ^a   Kinloch, Sabine ^b   Perrin, Luc ^c   Cooper, David ^d   Phillips, Andrew ^e   Hoen, Bruno ^f   Autran, Brigitte ^g   Sonnerborg, Anders ^h   Tsoukas, Chris ⁱ  

^a GLAXOSMITHKLINE   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF GENEVA   (Switzerland)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^f Besancon University Medical Centre   (France)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h KAROLINSKA INSTITUTE   (Sweden)

ⁱ MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; LAMIVUDINE PLUS ZIDOVUDINE;

BIOMEDICINE; DRUG INDUSTRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LETTER; MEDICAL RESEARCH; PRIORITY JOURNAL;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0033678138     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/81251     Document Type: Letter

References (3)

1. Industry outlines its perspective on new Third-World vaccine development
2. + T cells provides a mechanism for lifelong persistence of HIV-1 even in patients on effective combination therapy
3. + T cell responses associated with control of viremia